Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance
- 1 January 2006
- journal article
- Published by Elsevier in Advances in Enzyme Regulation
- Vol. 46 (1) , 249-279
- https://doi.org/10.1016/j.advenzreg.2006.01.004
Abstract
No abstract availableKeywords
This publication has 97 references indexed in Scilit:
- The complexity of PTEN: mutation, marker and potential target for therapeutic interventionEmerging Therapeutic Targets, 2004
- Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to GefitinibNew England Journal of Medicine, 2004
- BRAF mutations in non-Hodgkin's lymphomaBritish Journal of Cancer, 2003
- Differential effects of kinase cascade inhibitors on neoplastic and cytokine-mediated cell proliferationLeukemia, 2003
- Inhibition of caspase-9 through phosphorylation at Thr 125 by ERK MAPKNature Cell Biology, 2003
- Involvement of PI3K/Akt pathway in cell cycle progression, apoptosis, and neoplastic transformation: a target for cancer chemotherapyLeukemia, 2003
- RAF/RAS oncogenes and mismatch-repair statusNature, 2002
- Mutations of the BRAF gene in human cancerNature, 2002
- Tyrosine phosphorylation of the p85 subunit of phosphatidylinositol 3-kinase correlates with high proliferation rates in sublines derived from the Jurkat leukemiaThe International Journal of Biochemistry & Cell Biology, 2000
- Antiapoptosis potential of bcl-2 oncogene by dephosphorylationBiochemistry and Cell Biology, 1994